Article
Are all the IL-23 blockers the same in inflammatory bowel disease? - Nature Reviews Gastroenterology & Hepatology
Rating:
0.0
Views:
26
Likes:
1
Library:
1
A substantial percentage of patients with inflammatory bowel disease (IBD) exhibit biologic treatment failure or loss of response over time. This article explores the effectiveness and safety of monoclonal antibodies targeting the IL-23 pathway in treating IBD; continued research is needed to address lingering questions regarding long-term safety and efficacy.
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value